Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, With Particular Reference to Liver Safety

Author:Giovannoni, Gavin   Leist, Thomas   Jack, Dominic   Galazka, Andrew   Nolting, Axel   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.010  

Author Institution:Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom  Division of Clinical Neuroimmunology, Jefferson University, Comprehensive MS Center, Philadelphia, PA  Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA, Darmstadt, Germany, Feltham, United Kingdom  Ares Trading S.A., Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany, Eysins, Switzerland  the healthcare business of Merck KGaA, Darmstadt, Germany, Darmstadt, Germany  

Sleep Disturbances in Early Onset Parkinsonism

Author:McCarter, Stuart   Camerucci, Emanuele   Mullan, Aidan   Stang, Cole   Turcano, Pierpaolo   St. Louis, Erik   Boeve, Bradley   Bower, James   Savica, Rodolfo   

Session Name:P7: Movement Disorders: Parkinson's Disease Non-motor Symptoms 2  

Topic:Movement Disorders  

Program Number:P7.010  

Author Institution:Mayo Clinic, Rochester, MN  Kansas University Medical Center, Kansas City, KS  Mayo Clinic, Duluth, MN  Mayo Clinic, Jacksonville, FL  

Impact of cognitive exertion on autonomic reactivity in individuals with persistent post-concussive symptoms

Author:Moore, R. Davis   Harrison, Adam   Broglio, Steven   Herter, Troy   

Session Name:P7: Neuro Trauma and Sports Neurology: Symptoms and Therapies  

Topic:Neuro Trauma and Sports Neurology  

Program Number:P7.010  

Author Institution:University of South Carolina, Columbia, SC  University of South Carolina, West Columbia, SC  NeuroTrauma Research Laboratory, Ann Arbor, MI  Universty of South Carolina, Columbia, SC